Sanofi has completed its acquisition of Dynavax Technologies Corporation, bringing the adult hepatitis B vaccine HEPLISAV-B and several vaccine pipeline projects, including a shingles vaccine candidate currently in phase 1⁄2 studies, into its portfolio. Dynavax will now operate as an indirect, wholly owned subsidiary of Sanofi, and its common stock will no longer be traded on the NASDAQ. This move expands Sanofi’s presence in adult immunization by combining Dynavax’s differentiated vaccines with Sanofi’s commercial reach and development capabilities. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001163976-en) on February 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

Reuters

SPDR S&P Biotech

iShares Global Healthcare

iShares US Pharma

Sanofi

First Trust NYSE Arca Biotech Index Fd

VG Health

ALPS Medical Breakthrough

Health Care Select Sector SPDR

Dynavax Tech

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

iShares Biotechnology ETF

Sanofi Completes Acquisition of Dynavax Technologies